RADNOR,
Pa., Nov. 7, 2023 /PRNewswire/ -- NRx
Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the
"Company"), a late-stage biopharmaceutical company, today announced
that it will release its third quarter 2023 financial results after
the market closes on Tuesday, November 14,
2023, via press release, which will be available on the
Company's website at https://ir.nrxpharma.com/press-releases. The
Company will host a conference call to discuss the financial
results as well as provide a corporate update at 4:30 p.m. ET the same day.
The quarterly results and the conference call are anticipated to
include updates on recent progress related to development of
NRX-101 in the treatment of bipolar depression and timing of
clinical trials data, chronic pain, UTI and other indications, as
well as plans for NRX-100 (ketamine) development.
A live webcast of the conference call will be available on the
Company's website at https://ir.nrxpharma.com/events.
Participants that are unable to join the webcast can access the
conference call via telephone by dialing domestically
+1-855-327-6837 or internationally +1 1-631-891-4304.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical
company developing therapeutics based on its NMDA platform for the
treatment of central nervous system disorders, specifically
suicidal bipolar depression, chronic pain and PTSD. The Company is
developing NRX-101, an FDA-designated investigational Breakthrough
Therapy for suicidal treatment-resistant bipolar depression and
chronic pain. NRx has partnered with Alvogen Pharmaceuticals around
the development and marketing of NRX-101 for the treatment of
suicidal bipolar depression. NRX-101 additionally has potential to
act as a non-opioid treatment for chronic pain.
NRx has recently announced plans to submit a New Drug
Application for ketamine in the treatment of suicidal depression,
based on results of well-controlled clinical trials conducted under
the auspices of the US National Institutes of Health and newly
obtained data from French health authorities, licensed under a data
sharing agreement. NRx was awarded Fast Track Designation for
development of ketamine (NRX-100) by the US FDA as part of a
protocol to treat patients with acute suicidality.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-to-report-third-quarter-2023-financial-results-on-november-14-2023-301979598.html
SOURCE NRx Pharmaceuticals, Inc.